Icosapent
- Generic Name
- Icosapent
- Brand Names
- Animi-3 With Vitamin D
- Drug Type
- Small Molecule
- Chemical Formula
- C20H30O2
- CAS Number
- 10417-94-4
- Unique Ingredient Identifier
- AAN7QOV9EA
- Background
Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.
- Indication
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.
- Associated Therapies
- Dietary and Nutritional Therapies
Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial
- Conditions
- Coronary Artery Disease Progression
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Kobe University
- Target Recruit Count
- 50
- Registration Number
- NCT03192579
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
- Conditions
- Alzheimer's Disease
- Interventions
- Other: gel cap placebo
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 131
- Registration Number
- NCT02719327
- Locations
- 🇺🇸
William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
- Conditions
- Major Depressive DisorderOverweightInflammation
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT02553915
- Locations
- 🇺🇸
Depression Clinical and Research Program at Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Omega 3 for Treatment of Depression in Patients With Heart Failure
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Wei Jiang
- Target Recruit Count
- 108
- Registration Number
- NCT02057406
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction
- Conditions
- Coronary DiseaseMyocardial Infarction
- Interventions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 300
- Registration Number
- NCT01422317
- Locations
- 🇳🇴
Central Hospital in Rogalanad, Stavanger, Norway
A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 36
- Registration Number
- NCT00815685
- Locations
- 🇺🇸
Martin Memorial, Stuart, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
- Conditions
- DyskinesiaSchizophrenia
- First Posted Date
- 2005-06-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Stellenbosch
- Target Recruit Count
- 84
- Registration Number
- NCT00114595
- Locations
- 🇿🇦
Department of Psychiatry, Department of Health sciences, University of Stellenbosch, Cape Town, Western Cape, South Africa
Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress
- Conditions
- Healthy
- First Posted Date
- 2001-04-09
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Target Recruit Count
- 97
- Registration Number
- NCT00014027
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.